Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AVB-114, the ...

Six more personnel moves and a bevy of partnerships highlight the week that was.

Truist Financial analyst Michael Lewis maintained a Hold rating on AvalonBay (AVB – Research Report) today and set a price target of $230.00.

This was the stock's sixth consecutive day of losses.

Truist raised the firm’s price target on AvalonBay (AVB) to $230 from $229 and keeps a Hold rating on the shares as part of a broader research ...

This was the stock's fifth consecutive day of losses.

The sale is expected to close on or around March 31. In addition, AVB entered into an agreement with BSR REIT, BSR Trust and certain holders of Class B units of BSR Trust to purchase six ...

Compelling results from a Mayo Clinic Phase I trial ("STOMP-I") led to the founding of Avobis Bio and primary endpoint results from the Phase II trial ("STOMP-II) of AVB-114 are expected in mid-2025.

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...